“we will be looking to raise more over the course of the next six months.”
→ Read the source episode
StepPharma announces completion of new funding round by 2027-01-12
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Andy Parker predicts ET trial will recruit 50 patients by summer 2027 and be phase three ready by end of 2027.
Andy Parker predicts StepPharma will complete ET phase two by end of 2027 and begin planning phase three.
Andy Parker predicts phase one readout from solid tumor safety expansion cohorts within 12-15 months (by October 2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.